Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20221707 | 0.87 | MEN1 (0.40) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL23690778 | 0.87 | MEN1 (0.40) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL21152809 | 0.85 | C3AR1 (0.35) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL24591799 | 0.82 | SIRT6 (0.35) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL13167779 | 0.81 | FOLH1 (0.59) | MEN1KMT2AGAAFOLH1SMN1; SMN2 | |
| SCHEMBL19381704 | 0.81 | FOLH1 (0.59) | MEN1KMT2AGAAFOLH1SMN1; SMN2 | |
| SCHEMBL93364 | 0.81 | C3AR1 (0.47) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL30404095 | 0.81 | C3AR1 (0.47) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL93363 | 0.81 | C3AR1 (0.47) | C3AR1MEN1KMT2AGAAFOLH1 | |
| SCHEMBL24805405 | 0.81 | C3AR1 (0.48) | C3AR1MEN1KMT2AGAAFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | C3AR1 1418/4885MEN1 4125/4885KMT2A 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.